Mengxue Zhang

12 Wulumuqi Middle Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Superiority of high-dose cytarabine-based mobilisation over cyclophosphamide or plerixafor in primary CNS lymphoma.

Superiority of high-dose cytarabine-based mobilisation over cyclophosphamide or plerixafor in primary CNS lymphoma.

Journal: Annals of hematology
Published: November 13, 2025

Exosomal ANGPTL2 in cerebrospinal fluid as a novel prognostic biomarker for primary central nervous system lymphoma.

Exosomal ANGPTL2 in cerebrospinal fluid as a novel prognostic biomarker for primary central nervous system lymphoma.

Journal: Frontiers in immunology
Published: September 05, 2025

Investigation of MRI features in subtypes of primary central nervous system diffuse large B-cell lymphoma.

Investigation of MRI features in subtypes of primary central nervous system diffuse large B-cell lymphoma.

Journal: BMC medical imaging
Published: June 03, 2025

Antiepileptic drugs failed to prevent initial seizures or improve survival outcomes in patients with primary CNS lymphoma.

Antiepileptic drugs failed to prevent initial seizures or improve survival outcomes in patients with primary CNS lymphoma.

Journal: Scientific reports
Published: January 12, 2025

A Nomogram for Predicting Overall Survival in Primary Central Nervous System Lymphoma: A Retrospective Study.

A Nomogram for Predicting Overall Survival in Primary Central Nervous System Lymphoma: A Retrospective Study.

Journal: Journal of inflammation research
Published: October 06, 2024

Metabolic pathway alterations in cerebrospinal fluid as diagnostic biomarkers for primary central nervous system lymphoma.

Metabolic pathway alterations in cerebrospinal fluid as diagnostic biomarkers for primary central nervous system lymphoma.

Journal: Clinica chimica acta; international journal of clinical chemistry
Published: August 14, 2024

Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors.

Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors.

Journal: Frontiers in immunology
Published: November 23, 2023

Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma.

Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma.

Journal: Hematology (Amsterdam, Netherlands)
Published: August 07, 2023

Zanubrutinib plus Cytarabine in Patients with Refractory/Relapsed Primary Central Nervous System Lymphoma.

Zanubrutinib plus Cytarabine in Patients with Refractory/Relapsed Primary Central Nervous System Lymphoma.

Journal: Acta haematologica
Published: July 29, 2023

High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers.

High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers.

Journal: Frontiers in molecular biosciences
Published: July 11, 2023

Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma.

Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma.

Journal: Frontiers in immunology
Published: March 21, 2023

Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study.

Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study.

Journal: Frontiers in oncology
Published: May 07, 2022
Showing 1-12 of 14

Last Updated: 09/26/2026